Liquid Biopsy Based Multiomics Study for Colorectal Cancer Early Screening
Launched by SIR RUN RUN SHAW HOSPITAL · Feb 6, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new blood test called CRC-Appareo, which aims to help detect colorectal cancer and advanced precancerous growths known as adenomas in people who are at high risk. The goal is to see how well this test works compared to the traditional method of colonoscopy, which doctors currently use to find these issues. Additionally, the study will compare the new test to a commonly used stool test called the FIT (Fecal Immunochemical Test) to see which is better at identifying advanced neoplasia.
To participate in the trial, individuals must be willing to provide blood and stool samples and meet certain criteria. Those in the high-risk group should be scheduled for a colonoscopy and may have a family history of colorectal cancer or specific gastrointestinal symptoms. Patients who have already been diagnosed with colorectal cancer and have not yet received treatment are also eligible. The trial is not yet recruiting, but if someone is interested, they can expect to help advance cancer screening methods while contributing to important research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Willing to provide written consent Able to provide blood and stool samples
- For high risk CRC screening group:
- • Scheduled for colonoscopy voluntarily or by physician prescription
- CRC high risk profile as defined below:
- • History of FIT positivity Family history of CRC Any of two of the following clinical symptoms: chronic constipation/diarrhea, stool with mucous, chronic appendicitis, chronic bilary track diseases, mental stress
- For CRC group:
- • Confirmed CRC patients No prior treatment with chemotherapy, radiotherapy, and prior to any surgical procedures
- Exclusion Criteria:
- • Unwilling to provide blood samples FAP (familial adenomatous polyposis), Crohn's disease, ulcerative colitis Prior history of colonoscopy within the past 5 years and removal of lesions History of CRC other conditions deemed not suited for the study by investigators
About Sir Run Run Shaw Hospital
Sir Run Run Shaw Hospital is a distinguished medical institution dedicated to advancing healthcare through innovative clinical research and high-quality patient care. As a leading sponsor of clinical trials, the hospital integrates state-of-the-art medical technology with a commitment to ethical standards and patient safety. With a multidisciplinary team of experienced healthcare professionals, Sir Run Run Shaw Hospital focuses on a wide range of therapeutic areas, aiming to contribute to medical knowledge and improve treatment outcomes. The institution fosters collaboration with academic and industry partners to drive scientific discovery and enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Trial Officials
sheng dai, MD&PhD
Principal Investigator
Sir Run Run Shaw Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported